Robert J. Heine

Eli Lilly (United States) — United States

Medicine · Health Sciences

103h-index45.6kcitations438works4.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Management and Research(123), Diabetes, Cardiovascular Risks, and Lipoproteins(109), Diabetes Treatment and Management(88), Metabolism, Diabetes, and Cancer(59), Diabetes Management and Education(51)

Publications437 total

Disease burden, clinical care gap, and intent to prescribe diabetes polypill to Indian patients with type 2 diabetes
Diabetes Research and Clinical Practice·2025Open Access
Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review
Diabetes Obesity and Metabolism·2025· 1 citedOpen Access
Author response for "Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review"
2025
Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test
The Journal of Clinical Endocrinology & Metabolism·2024· 16 citedOpen Access
Early-onset type 2 diabetes and tirzepatide treatment: a post hoc analysis from the SURPASS clinical trial program
2024Open Access
Early-onset type 2 diabetes and tirzepatide treatment: a post hoc analysis from the SURPASS clinical trial program
2024Open Access
Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program
Diabetes Care·2024· 11 citedOpen Access
How the eyes habituate to the changing appearance of the patient: the advantage of a fresh look
2023
Diabetes registries and high-quality diabetes care
The Lancet Diabetes & Endocrinology·2023· 9 cited
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies ( <scp>SURPASS</scp> programme)
Diabetes Obesity and Metabolism·2022· 22 citedOpen Access
The European Diabetes Forum (EUDF): a forum for turning the tide on diabetes in Europe
Diabetologia·2022· 7 citedOpen Access
Efficacy and Safety of Tirzepatide versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Diabetologie und Stoffwechsel·2022· 10 cited
Long-COVID aus Sicht der Anthroposophischen Medizin – Symptome und Behandlungsmöglichkeiten. Empfehlungen einer internationalen Expertenkommission für medizinische Fachkräfte
Der Merkurstab·2022· 4 cited
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
The Lancet·2021· 588 cited
Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States
Diabetes Therapy·2021· 25 citedOpen Access
Evaluating glucose‐lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial
Diabetes Obesity and Metabolism·2020· 17 citedOpen Access
Privatkopie Im Digitalen Zeitalter (Private Copying in the Digital Age)
SSRN Electronic Journal·2020Open Access
Review for "Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL"
2019Open Access
1278-P: Innovative Quality Improvement Medical Education Program for General Practitioners in Japan
Diabetes·2019
467-P: Estimation of 10-Year Cardiovascular Risk among Newly Diagnosed Type 2 Diabetes Patients in the “Evaluation of Effectiveness of Treatment Paradigm for Newly Diagnosed Type 2 Diabetes Patients in China (NEW2D)” Study Population
Diabetes·2019
page 1 of 22Next →

Frequent Co-authors

L.M. Bouter(25), Joost Dekker(23), Coen D.A. Stehouwer(19), Giel Nijpels(17), Michaëla Diamant(10), Piet J. Kostense(9), Pieter J. Kostense(7), Bernard Zinman(4), Agnes Jager(4), Ulf Smith(3), David M. Nathan(3), Mayer B. Davidson(3), Ronald M.A. Henry(3), John Yudkin(3), Roger K. Schindhelm(3), Mathijs C. Bunck(3), P.A. Grootenhuis(3), Gordon Murray(2), John B. Buse(2), Rury R. Holman(2)